Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;21(3):353-364.
doi: 10.1080/14737167.2021.1848553. Epub 2020 Dec 1.

Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews

Vakaramoko Diaby  1 , Reem D Almutairi  2 , Aram Babcock  1 , Richard K Moussa  3 , Askal Ali  4
Affiliations
Review

Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews

Vakaramoko Diaby et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun.

Abstract

Introduction: Treatment of human epithelial growth factor receptor 2 (HER2)-positive breast cancer has rapidly evolved over the past decades with the addition of trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1). These treatments have dramatically impacted the survival of HER2-positive metastatic breast cancer (mBC) patients. Nonetheless, these agents are associated with high price tags, begging the question, 'Are treatments for HER2-positive metastatic breast cancer and associated metastases cost-effective'?Areas covered: We examine evidence on the cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases through a review of systematic reviews on the topic. Additionally, we discuss the implications of our findings and provide recommendations for future directions in the assessment of the cost-effectiveness of targeted directed agents for HER2-positive mBC.Expert opinion: Heterogeneous evidence from cost-effectiveness studies on the use of targeted directed agents for HER2-positive mBC across the world caution against cross-country comparisons of the value of such treatments. It also militates in favor of the production and use of cost-effectiveness analyses for local rather than global decision-making, thus ensuring that economic evaluations reflect the needs of local decision-makers and populations for which they are devised.

Keywords: Breast cancer; cost-effectiveness; her2-positive receptors; metastases; systematic review.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study selection process of articles iincluded in final analysis. BC: breast cancer.
Figure 2.
Figure 2.
Main characteristics of systematic reviews- Part A.
Figure 3.
Figure 3.
Main characteristics of systematic reviews- Part B.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. [Internet]. - PubMed
    1. American Cancer Society. Cancer facts& figures 2020. Atlanta, Ga: American Cancer Society; 2020. - PMC - PubMed
    1. Kwan ML, Ergas IJ, Somkin CP, et al. Quality of life among women recently diagnosed with invasive breast cancer: the pathways study. Breast Cancer Res Treat. 2010;123:507–524. [Internet]. - PMC - PubMed
    1. Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712. [Internet]. - PubMed
    1. Controlling Healthcare Costs While Promoting the Best Possible Health Outcomes [Internet]. [cited 2020 Aug 28]. Available from: http://www.acponline.org/advocacy/where_we_stand/policy/controlling_heal....